• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (1)
    • Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.
    • See All Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.

Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. J Natl Cancer Inst. 2015 Dec; 107(12):djv274.

View in: PubMed

subject areas
  • Adenocarcinoma
  • Adipose Tissue
  • Administration, Oral
  • Animals
  • Cachexia
  • Carcinoma, Lewis Lung
  • Colonic Neoplasms
  • Cytokines
  • Forkhead Box Protein O1
  • Forkhead Transcription Factors
  • Gene Expression Regulation
  • Histone Deacetylase Inhibitors
  • Interleukin-6
  • Ion Channels
  • Leukemia Inhibitory Factor
  • Lipase
  • MEF2 Transcription Factors
  • Mice
  • Mitochondrial Proteins
  • Muscle Proteins
  • Muscle Strength
  • Muscle, Skeletal
  • Neoplasms, Experimental
  • Phenylbutyrates
  • Receptors, Interleukin-6
  • SKP Cullin F-Box Protein Ligases
  • Survival Analysis
  • Tripartite Motif Proteins
  • Ubiquitin-Protein Ligases
  • Uncoupling Protein 3
  • Weight Loss

authors with profiles
  • Denis C Guttridge